These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 430373)

  • 1. Effects of physostigmine, atropine and scopolamine on behavior maintained by a multiple schedule of food presentation in the mouse.
    Wenger GR
    J Pharmacol Exp Ther; 1979 Apr; 209(1):137-43. PubMed ID: 430373
    [No Abstract]   [Full Text] [Related]  

  • 2. Behavioral modulation of the cardiovascular effects of l-norepinephrine in the squirrel monkey.
    Kelleher RT; Morse WH; Goldberg SR; Herd JA
    J Pharmacol Exp Ther; 1974 Nov; 191(2):269-83. PubMed ID: 4371767
    [No Abstract]   [Full Text] [Related]  

  • 3. Tolerance to the behavioural effects of physostigmine in rats: lack of importance of behavioural compensation.
    Overstreet DH; Dubas G
    Commun Psychopharmacol; 1978; 2(2):93-8. PubMed ID: 668303
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of selective central muscarinic blockade on schedule-controlled behavior and on the rate-decreasing effects of physostigmine.
    Hymowitz N; Brezenoff HE
    Pharmacol Biochem Behav; 1984 Jul; 21(1):109-15. PubMed ID: 6463084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Physostigmine-insensitive behavioral excitatory effects of atropine in squirrel monkeys.
    Witkin JM; Markowitz RA; Barrett JE
    Pharmacol Biochem Behav; 1989 Jan; 32(1):309-15. PubMed ID: 2734342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interactions between scopolamine and muscarinic cholinergic agonists or cholinesterase inhibitors on spatial alternation performance in rats.
    Shannon HE; Bemis KG; Hendrix JC; Ward JS
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1071-7. PubMed ID: 2262893
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship of the behavioral effects of aprophen, atropine and scopolamine to antagonism of the behavioral effects of physostigmine.
    Genovese RF; Elsmore TF; Witkin JM
    Pharmacol Biochem Behav; 1990 Sep; 37(1):117-22. PubMed ID: 2263653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of anticholinergic and cholinesterase blocking drugs on appetitive behavior under different deprivation conditions.
    Adams PM
    Life Sci; 1977 Jul; 21(1):129-36. PubMed ID: 886911
    [No Abstract]   [Full Text] [Related]  

  • 9. The effects of scopolamine and physostigmine on fixed-interval behaviour in the rat.
    McKim WA
    Psychopharmacologia; 1974; 39(3):237-44. PubMed ID: 4427990
    [No Abstract]   [Full Text] [Related]  

  • 10. Modulation of cholinergic activity and the aversive threshold in the rat.
    Houser VP; Van Hart DA
    Pharmacol Biochem Behav; 1974; 2(5):631-7. PubMed ID: 4431827
    [No Abstract]   [Full Text] [Related]  

  • 11. Separating the effects of response rate and reinforcement frequency in the rate-dependent effects of amphetamine and scopolamine on the schedule-controlled performance of rats and pigeons.
    MacPhail RC; Gollub LR
    J Pharmacol Exp Ther; 1975 Aug; 194(2):332-42. PubMed ID: 1151762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of azaprophen, scopolamine and trihexyphenidyl on schedule-controlled behavior, before and after chronic physostigmine.
    Genovese RF
    Eur J Pharmacol; 1990 Feb; 176(3):271-9. PubMed ID: 2328755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Berry CA: Effect of cholinergic drugs on passive avoidance in the mouse.
    Dilts SL
    J Pharmacol Exp Ther; 1967 Nov; 158(2):279-85. PubMed ID: 6065151
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of atropine and related drugs on the EEG and behaviour.
    Bradley PB
    Prog Brain Res; 1968; 28():3-13. PubMed ID: 4301741
    [No Abstract]   [Full Text] [Related]  

  • 15. The interaction between beta-phenylethylamine and agents which affect the cholinergic nervous system on locomotor activity and toxicity in mice.
    Jackson DM
    Arzneimittelforschung; 1974 Jan; 24(1):24-7. PubMed ID: 4406104
    [No Abstract]   [Full Text] [Related]  

  • 16. Scopolamine self-administration: cholinergic involvement in reward mechanisms.
    Glick SD; Guido RA
    Life Sci; 1982 Aug; 31(9):909-13. PubMed ID: 7176819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Comparison of certain central effects of atropine, scopolamine and their quaternary ammonium derivatives in animals].
    Malatray J; Simon P
    Therapie; 1972; 27(1):153-66. PubMed ID: 5017551
    [No Abstract]   [Full Text] [Related]  

  • 18. Impairment of one-trial passive avoidance learning in mice by scopolamine, scopolamine methylbromide, and physostigmine.
    Bohdanecký Z; Jarvik ME
    Int J Neuropharmacol; 1967 May; 6(3):217-22. PubMed ID: 6037526
    [No Abstract]   [Full Text] [Related]  

  • 19. Discriminative stimulus properties of physostigmine in rats.
    Tang AH; Franklin SR
    Eur J Pharmacol; 1988 Aug; 153(1):97-104. PubMed ID: 3215280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of atropine, hyoscyamine, physostigmine and neostigmine on the electrical activity of the brain of the conscious cat.
    BRADLEY PB; ELKES J
    J Physiol; 1953 Apr; 120(1-2):14P-15P. PubMed ID: 13062251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.